Skip to Content
MilliporeSigma

Advances in amblyopia: what have we learned from PEDIG trials?

Pediatrics (2013-02-06)
Kammi B Gunton
ABSTRACT

Amblyopia is the most common cause of preventable visual loss in children. This article reviews treatment options, durations, and efficacy in randomized multicentered trials conducted by the Pediatric Eye Disease and Investigator Group in the last decade. Parents and patients should be counseled that many forms of treatment are efficacious, allowing the option of choice of best-tolerated treatment method. Compliance is key to successful treatment. The course of treatment is likely at least 6-12 months, with yearly follow-up suggested once amblyopia has been treated to monitor for regression.

MATERIALS
Product Number
Brand
Product Description

Supelco
Atropine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Atropine for peak identification, European Pharmacopoeia (EP) Reference Standard